6534 — CH Biotech R&D Co Share Price
0.000.00%
Last trade - 00:00- TWD7.81bn
- TWD8.08bn
- TWD1.64bn
- 77
- 47
- 50
- 64
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.95 | ||
| Price to Tang. Book | 2.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.78 | ||
| EV to EBITDA | 11.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.24% | ||
| Return on Equity | 18.44% | ||
| Operating Margin | 33.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 702.19 | 1,018.5 | 1,434.12 | 1,514.83 | 1,635.74 | n/a | n/a | 14.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -48.82 | +191.94 | +58.99 | +0.21 | -2.68 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CH Biotech R&D Co Ltd is a Taiwan-based company mainly engaged in the research, development, production and sales of new agricultural biotechnology drugs. The main products include plant growth regulators (PGR) and fertilizers. PGR products include MegaGro L (Radiate), Promote (On Ward, AGX21028/InnoCharge), Persevere (Endurance), Promote Max (OnWard Max) and MegaGro 2.0 (Radiate NEXT). The fertilizers are special fertilizers, and its products include NutriSync D/MicroSync D, NutriSync M/MicroSync M, NutriSync 3D and additives (CHB 6030, CHB 7001, CHB6020). The Company distributes its products to North America, South America, Australia and Asia markets.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 29th, 2013
- Public Since
- July 2nd, 2015
- No. of Employees
- 22
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 102,800,000
- Address
- No.89, Wenxian Road, Neixingli, NANTOU, 540
- Web
- https://www.chbio.com.tw/
- Phone
- +886 497009198
- Contact
- Ager Lin
- Auditors
- KPMG LLP
Upcoming Events for 6534
Similar to 6534
All Cosmos Bio-Tech Holding
Taiwan Stock Exchange
Acelon Chemicals & Fiber
Taiwan Stock Exchange
Amia Co
Taiwan Stock Exchange
Allied Supreme
Taiwan Stock Exchange
Asia Polymer
Taiwan Stock Exchange
FAQ
What is the CH Biotech R&D Co share price?
As of Today at 19:52 UTC, shares in CH Biotech R&D Co are trading at TWD76.00. This share price information is delayed by 15 minutes.
How has the CH Biotech R&D Co share price performed this year?
Shares in CH Biotech R&D Co last closed at TWD76.00 and the price had moved by -8.43% over the past 365 days. In terms of relative price strength the CH Biotech R&D Co share price has underperformed the FTSE Developed Asia Pacific Index by -7.39% over the past year.
What are the analyst and broker recommendations for CH Biotech R&D Co?
There is no consensus recommendation for this security.
Find out moreWhat is the CH Biotech R&D Co dividend yield?
The CH Biotech R&D Co dividend yield is 5.39% based on the trailing twelve month period.
Does CH Biotech R&D Co pay a dividend?
Last year, CH Biotech R&D Co paid a total dividend of TWD4.10, and it currently has a trailing dividend yield of 5.39%. We do not have any data on when CH Biotech R&D Co is to next pay dividends.
When does CH Biotech R&D Co next pay dividends?
We do not have data on when CH Biotech R&D Co is to next pay dividends. The historic dividend yield on CH Biotech R&D Co shares is currently 5.39%.
How do I buy CH Biotech R&D Co shares?
To buy shares in CH Biotech R&D Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CH Biotech R&D Co?
As of the previous close price of TWD76.00, shares in CH Biotech R&D Co had a market capitalisation of TWD7.81bn.
Where are CH Biotech R&D Co shares listed?
Here are the trading details for CH Biotech R&D Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6534
What kind of share is CH Biotech R&D Co?
Based on an overall assessment of its quality, value and momentum CH Biotech R&D Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CH Biotech R&D Co share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the CH Biotech R&D Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CH Biotech R&D Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -0.46%.
As of the last closing price of TWD76.00, shares in CH Biotech R&D Co were trading -5.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CH Biotech R&D Co PE Ratio?
The CH Biotech R&D Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD76.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CH Biotech R&D Co?
We do not have data on CH Biotech R&D Co's directors